BRPI1010739A2 - formas de dosagens de apixaban. - Google Patents
formas de dosagens de apixaban.Info
- Publication number
- BRPI1010739A2 BRPI1010739A2 BRPI1010739A BRPI1010739A BRPI1010739A2 BR PI1010739 A2 BRPI1010739 A2 BR PI1010739A2 BR PI1010739 A BRPI1010739 A BR PI1010739A BR PI1010739 A BRPI1010739 A BR PI1010739A BR PI1010739 A2 BRPI1010739 A2 BR PI1010739A2
- Authority
- BR
- Brazil
- Prior art keywords
- apixaban
- dosage forms
- dosage
- forms
- Prior art date
Links
- QNZCBYKSOIHPEH-UHFFFAOYSA-N Apixaban Chemical compound C1=CC(OC)=CC=C1N1C(C(=O)N(CC2)C=3C=CC(=CC=3)N3C(CCCC3)=O)=C2C(C(N)=O)=N1 QNZCBYKSOIHPEH-UHFFFAOYSA-N 0.000 title 1
- 229960003886 apixaban Drugs 0.000 title 1
- 239000002552 dosage form Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US18744209P | 2009-06-16 | 2009-06-16 | |
| PCT/US2010/038660 WO2010147978A1 (en) | 2009-06-16 | 2010-06-15 | Dosage forms of apixaban |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1010739A2 true BRPI1010739A2 (pt) | 2016-03-15 |
Family
ID=42677548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1010739A BRPI1010739A2 (pt) | 2009-06-16 | 2010-06-15 | formas de dosagens de apixaban. |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20120087978A1 (enExample) |
| EP (2) | EP2442791B1 (enExample) |
| JP (1) | JP5775071B2 (enExample) |
| KR (1) | KR20120029428A (enExample) |
| CN (1) | CN102802608A (enExample) |
| AU (1) | AU2010260208B2 (enExample) |
| BR (1) | BRPI1010739A2 (enExample) |
| CA (1) | CA2765413A1 (enExample) |
| CY (1) | CY1122685T1 (enExample) |
| DK (1) | DK2442791T3 (enExample) |
| ES (1) | ES2769357T3 (enExample) |
| HR (1) | HRP20200297T1 (enExample) |
| HU (1) | HUE048542T2 (enExample) |
| IL (1) | IL216421A0 (enExample) |
| LT (1) | LT2442791T (enExample) |
| MX (1) | MX2011013080A (enExample) |
| PL (1) | PL2442791T3 (enExample) |
| PT (1) | PT2442791T (enExample) |
| RU (1) | RU2012101214A (enExample) |
| SG (1) | SG176785A1 (enExample) |
| SI (1) | SI2442791T1 (enExample) |
| SM (1) | SMT202000093T1 (enExample) |
| WO (1) | WO2010147978A1 (enExample) |
| ZA (1) | ZA201109334B (enExample) |
Families Citing this family (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210124532A (ko) * | 2010-02-25 | 2021-10-14 | 브리스톨-마이어스 스퀴브 홀딩스 아일랜드 언리미티드 컴퍼니 | 아픽사반 제제 |
| CN103458879A (zh) * | 2011-03-25 | 2013-12-18 | 西莱克塔生物科技公司 | 渗透性介导释放型合成纳米载体 |
| EP2554159A1 (en) | 2011-08-04 | 2013-02-06 | ratiopharm GmbH | Dosage forms comprising apixaban and content uniformity enhancer |
| WO2013164839A2 (en) * | 2012-03-06 | 2013-11-07 | Cadila Healthcare Limited | Amorphous form of apixaban, process of preparation and compositions thereof |
| EP2836206A4 (en) * | 2012-04-10 | 2015-11-04 | Rubicon Res Private Ltd | PHARMACEUTICAL FORMULATIONS WITH CONTROLLED RELEASE OF DIRECT THROMBINS |
| EP2854759B1 (en) | 2012-05-24 | 2019-12-18 | ratiopharm GmbH | Dosage forms comprising apixaban and matrix former |
| US8313774B1 (en) | 2012-06-26 | 2012-11-20 | Magnifica Inc. | Oral solid composition |
| EP2900217A1 (en) * | 2012-09-26 | 2015-08-05 | Bristol-Myers Squibb Company | Apixaban liquid formulations |
| CN104721156B (zh) * | 2013-12-18 | 2020-05-01 | 山东新时代药业有限公司 | 一种含利伐沙班的片剂 |
| WO2015097090A1 (en) * | 2013-12-23 | 2015-07-02 | Laboratorios Del Dr. Esteve, S.A. | Oral pharmaceutical composition |
| EP2907507A1 (en) * | 2014-02-17 | 2015-08-19 | Sandoz Ag | Pharmaceutical composition comprising apixaban |
| CN104971355B (zh) * | 2014-04-02 | 2018-04-24 | 上海现代药物制剂工程研究中心有限公司 | 含有利伐沙班的组合物及其制备方法 |
| US20150335586A1 (en) | 2014-05-20 | 2015-11-26 | R.P. Scherer Technologies, Llc | Capsule dispensing container |
| JP6359390B2 (ja) * | 2014-09-05 | 2018-07-18 | テルモ株式会社 | インプラントデバイスおよびインプラントデバイス植え込み具 |
| WO2017088841A1 (en) | 2015-11-26 | 2017-06-01 | Zentiva, K.S. | Preparation of a drug form containing amorphous apixaban |
| CN106902115A (zh) * | 2015-12-22 | 2017-06-30 | 江苏万邦生化医药股份有限公司 | 阿哌沙班在治疗糖尿病足药物中的应用 |
| US10537524B2 (en) | 2016-01-12 | 2020-01-21 | North & South Brother Pharmacy Investment Company Limited | Apixaban solid composition and preparation method thereof |
| CN106986868B (zh) * | 2016-01-21 | 2020-04-21 | 广东东阳光药业有限公司 | 包含阿哌沙班的共晶体及其制备方法 |
| US11154558B2 (en) * | 2016-04-15 | 2021-10-26 | Adams Pharmaceuticals LLC | Prevention of atherosclerotic events with direct factor Xa inhibitors |
| WO2017221209A1 (en) | 2016-06-23 | 2017-12-28 | Lupin Limited | Pharmaceutical formulations of apixaban |
| CN108236604A (zh) * | 2018-02-07 | 2018-07-03 | 中国药科大学 | 阿哌沙班柔性脂质体 |
| AU2019226030B2 (en) * | 2018-02-21 | 2025-02-20 | Aron H. BLAESI | Expanding structured dosage form |
| PL3781132T3 (pl) * | 2018-04-16 | 2024-05-20 | Bristol-Myers Squibb Company | Preparaty apiksabanu |
| KR20190130411A (ko) | 2018-05-14 | 2019-11-22 | 신일제약주식회사 | 아픽사반 약제학적 제제 및 그의 제조방법 |
| CA3109007A1 (en) * | 2018-08-14 | 2020-02-20 | Jiangsu Hengrui Medicine Co., Ltd. | Injectable pharmaceutical composition and preparation method therefor |
| CN109010273B (zh) * | 2018-10-08 | 2021-03-19 | 中国药科大学 | 一种阿哌沙班纳米混悬剂及其制备方法 |
| KR102044676B1 (ko) * | 2019-03-27 | 2019-11-14 | 주식회사 씨트리 | 생체적합성 고분자 기반 아픽사반 함유 미립구의 제조방법 |
| KR102045721B1 (ko) | 2019-03-27 | 2019-11-18 | 주식회사 씨트리 | 아픽사반 함유 미립구 제조용 분산상의 조성물 및 이로부터 제조되는 생체적합성 고분자 기반 아픽사반 함유 미립구 |
| CN110037990B (zh) * | 2019-04-15 | 2023-03-28 | 海正药业(杭州)有限公司 | 一种阿哌沙班固体无定形分散体的制备工艺 |
| WO2020219384A1 (en) * | 2019-04-26 | 2020-10-29 | Taho Pharmaceuticals Ltd. | Apixaban transdermal delivery system and uses thereof |
| WO2020231791A1 (en) * | 2019-05-10 | 2020-11-19 | Fordoz Pharma Corp. | Injectable polymer nanoparticle compositions of antithrombotic agents and methods thereof |
| JP7752487B2 (ja) * | 2020-03-24 | 2025-10-10 | 日本ジェネリック株式会社 | アピキサバン含有固体分散体 |
| JP7520351B2 (ja) * | 2020-08-14 | 2024-07-23 | 日医工株式会社 | アピキサバン含有医薬組成物 |
| IL301389A (en) * | 2020-09-18 | 2023-05-01 | Bristol Myers Squibb Co | Dosage forms for tyk2 inhibitors comprising swellable cores |
| US20240041856A1 (en) * | 2020-12-13 | 2024-02-08 | Dafechem Limited | Liquid apixaban formulation in small dose volume |
| PH12023553262A1 (en) * | 2021-06-08 | 2024-03-25 | Taho Pharmaceuticals Ltd | Apixaban film product and uses thereof |
| CN115715770B (zh) * | 2021-08-24 | 2024-01-26 | 新领医药技术(深圳)有限公司 | 阿哌沙班透皮贴剂及其制备方法 |
| US12213972B2 (en) * | 2022-07-27 | 2025-02-04 | Slayback Pharma Llc | Stable pharmaceutical compositions of apixaban |
| KR20240102908A (ko) * | 2022-12-26 | 2024-07-03 | 주식회사 렉스팜텍 | 아픽사반을 포함하는 서방성 정제 |
| WO2024220731A1 (en) * | 2023-04-18 | 2024-10-24 | Incyclix Bio, Llc. | Advantageous human dosage regimens for administration of inx-315 |
| WO2024261686A1 (en) * | 2023-06-23 | 2024-12-26 | Ronak Patel | A gastroretentive composition comprising apixaban |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3995631A (en) | 1971-01-13 | 1976-12-07 | Alza Corporation | Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4247498A (en) | 1976-08-30 | 1981-01-27 | Akzona Incorporated | Methods for making microporous products |
| US4564488A (en) | 1978-07-31 | 1986-01-14 | Akzo Nv | Methods for the preparation of porous fibers and membranes |
| US4203440A (en) | 1978-10-23 | 1980-05-20 | Alza Corporation | Device having variable volume chamber for dispensing useful agent |
| CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| EP0028489B1 (en) | 1979-11-05 | 1983-10-05 | Beecham Group Plc | Enzyme derivatives, and their preparation |
| US4490431A (en) | 1982-11-03 | 1984-12-25 | Akzona Incorporated | 0.1 Micron rated polypropylene membrane and method for its preparation |
| US4612008A (en) | 1983-05-11 | 1986-09-16 | Alza Corporation | Osmotic device with dual thermodynamic activity |
| US4627850A (en) | 1983-11-02 | 1986-12-09 | Alza Corporation | Osmotic capsule |
| US5225192A (en) | 1988-10-17 | 1993-07-06 | Vectorpharma International S.P.A. | Poorly soluble medicaments supported on polymer substances in a form suitable for increasing their dissolving rate |
| DE3438830A1 (de) | 1984-10-23 | 1986-04-30 | Rentschler Arzneimittel | Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung |
| DE3660408D1 (en) | 1985-02-27 | 1988-08-25 | Oerlikon Buehrle Ag | Apparatus for measuring the vibrations of a spiral bevel gear transmission in a gear-testing machine |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Dispensing devices powered by hydrogel |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| US5324280A (en) | 1990-04-02 | 1994-06-28 | Alza Corporation | Osmotic dosage system for delivering a formulation comprising liquid carrier and drug |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| DE69222847T3 (de) | 1991-04-16 | 2005-09-15 | Nippon Shinyaku Co., Ltd. | Verfahren zur herstellung einer festen dispersion |
| US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
| JP3265680B2 (ja) | 1992-03-12 | 2002-03-11 | 大正製薬株式会社 | 経口製剤用組成物 |
| DE4327063A1 (de) | 1993-08-12 | 1995-02-16 | Kirsten Dr Westesen | Ubidecarenon-Partikel mit modifizierten physikochemischen Eigenschaften |
| US6054136A (en) | 1993-09-30 | 2000-04-25 | Gattefosse S.A. | Orally administrable composition capable of providing enhanced bioavailability when ingested |
| US5458887A (en) | 1994-03-02 | 1995-10-17 | Andrx Pharmaceuticals, Inc. | Controlled release tablet formulation |
| GB9405304D0 (en) | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| US5612359A (en) | 1994-08-26 | 1997-03-18 | Bristol-Myers Squibb Company | Substituted biphenyl isoxazole sulfonamides |
| DE4440337A1 (de) | 1994-11-11 | 1996-05-15 | Dds Drug Delivery Services Ges | Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit |
| DE19504832A1 (de) | 1995-02-14 | 1996-08-22 | Basf Ag | Feste Wirkstoff-Zubereitungen |
| SI9500173B (sl) | 1995-05-19 | 2002-02-28 | Lek, | Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo |
| US5654005A (en) | 1995-06-07 | 1997-08-05 | Andrx Pharmaceuticals, Inc. | Controlled release formulation having a preformed passageway |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US5686133A (en) | 1996-01-31 | 1997-11-11 | Port Systems, L.L.C. | Water soluble pharmaceutical coating and method for producing coated pharmaceuticals |
| US5993858A (en) | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
| TW536540B (en) | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
| US6046177A (en) | 1997-05-05 | 2000-04-04 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations |
| US5874418A (en) | 1997-05-05 | 1999-02-23 | Cydex, Inc. | Sulfoalkyl ether cyclodextrin based solid pharmaceutical formulations and their use |
| US6492991B1 (en) | 1998-08-28 | 2002-12-10 | Ati International Srl | Method and apparatus for controlling compressed Z information in a video graphics system |
| KR20010083092A (ko) | 1998-07-06 | 2001-08-31 | 스티븐 비. 데이비스 | 이중 안지오텐신 엔도텔린 수용체 길항제로서의 비페닐술폰아미드 |
| KR100634069B1 (ko) | 1998-12-17 | 2006-10-16 | 알자 코포레이션 | 다중 코팅에 의한, 액체 충진 젤라틴 캡슐로부터 제어방출 시스템으로의 전환 |
| US6342249B1 (en) | 1998-12-23 | 2002-01-29 | Alza Corporation | Controlled release liquid active agent formulation dosage forms |
| EP1027887B1 (en) * | 1999-02-10 | 2008-08-13 | Pfizer Products Inc. | Matrix controlled release device |
| US6706283B1 (en) | 1999-02-10 | 2004-03-16 | Pfizer Inc | Controlled release by extrusion of solid amorphous dispersions of drugs |
| ATE433318T1 (de) * | 1999-02-10 | 2009-06-15 | Pfizer Prod Inc | Osmotisches system zur verabreichung von wirkstoffen, die feste amorphe dispersionen enthalten |
| US6548529B1 (en) | 1999-04-05 | 2003-04-15 | Bristol-Myers Squibb Company | Heterocyclic containing biphenyl aP2 inhibitors and method |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| CZ20022047A3 (cs) | 1999-12-23 | 2003-09-17 | Pfizer Products Inc. | Farmaceutické kompozice poskytující zvýšenou koncentraci léčiva |
| US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| JP2005500314A (ja) | 2001-06-21 | 2005-01-06 | ファイザー・プロダクツ・インク | コレステロールエステル転送蛋白インヒビターの自己乳化性製剤 |
| DE60220049T2 (de) * | 2001-06-22 | 2007-08-30 | Pfizer Products Inc., Groton | Pharmazeutische Zusammensetzung, umfassend eine feste Dispersion eines im Wasser schwer löslichen Arzneimittels und ein löslichkeitssteigerndes Polymer |
| CA2448825C (en) | 2001-06-22 | 2009-08-11 | Pfizer Products Inc. | Pharmaceutical compositions of adsorbates of amorphous drug |
| EP1269994A3 (en) | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
| TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
| JP2005522424A (ja) * | 2002-02-01 | 2005-07-28 | ファイザー・プロダクツ・インク | コレステリルエステル転移タンパク質インヒビターの制御放出性薬剤投与形態 |
| AR038375A1 (es) | 2002-02-01 | 2005-01-12 | Pfizer Prod Inc | Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo |
| JP4865989B2 (ja) | 2002-02-01 | 2012-02-01 | ベンド・リサーチ・インコーポレーテッド | 改良された噴霧乾燥装置を使用する均質な噴霧乾燥された固体の非晶質薬物分散物を製造する方法 |
| US20030175346A1 (en) | 2002-02-01 | 2003-09-18 | Anne Billotte | Osmotic delivery system |
| CA2534371A1 (en) | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| GB0417132D0 (en) | 2004-07-31 | 2004-09-01 | Koninkl Philips Electronics Nv | A shift register circuit |
| US7396932B2 (en) | 2004-09-28 | 2008-07-08 | Bristol-Myers Squibb Company | Process for preparing 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| US20060069085A1 (en) | 2004-09-28 | 2006-03-30 | Rulin Zhao | Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones |
| EP1685841A1 (en) | 2005-01-31 | 2006-08-02 | Bayer Health Care Aktiengesellschaft | Prevention and treatment of thromboembolic disorders |
| US20070191306A1 (en) * | 2005-08-17 | 2007-08-16 | Bristol-Myers Squibb Company | FACTOR Xa INHIBITOR FORMULATION AND METHOD |
| CN101340933A (zh) * | 2005-08-17 | 2009-01-07 | 百时美施贵宝公司 | 具有环糊精的因子xa抑制剂包合配合物 |
| US20070259913A1 (en) * | 2006-05-04 | 2007-11-08 | David Deitchman | Prophylaxis of thromboembolic events in cancer patients |
| PE20080661A1 (es) * | 2006-09-12 | 2008-06-12 | Glaxo Group Ltd | COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DEL FACTOR Xa |
| US20110045028A1 (en) | 2006-11-30 | 2011-02-24 | Takeda Pharmaceutical Company Limited | Sustained release preparation |
-
2010
- 2010-06-14 SM SM20200093T patent/SMT202000093T1/it unknown
- 2010-06-15 SG SG2011091519A patent/SG176785A1/en unknown
- 2010-06-15 KR KR1020117030021A patent/KR20120029428A/ko not_active Withdrawn
- 2010-06-15 US US13/378,236 patent/US20120087978A1/en not_active Abandoned
- 2010-06-15 BR BRPI1010739A patent/BRPI1010739A2/pt not_active Application Discontinuation
- 2010-06-15 MX MX2011013080A patent/MX2011013080A/es not_active Application Discontinuation
- 2010-06-15 PL PL10727611T patent/PL2442791T3/pl unknown
- 2010-06-15 HR HRP20200297TT patent/HRP20200297T1/hr unknown
- 2010-06-15 PT PT107276115T patent/PT2442791T/pt unknown
- 2010-06-15 DK DK10727611.5T patent/DK2442791T3/da active
- 2010-06-15 SI SI201031972T patent/SI2442791T1/sl unknown
- 2010-06-15 AU AU2010260208A patent/AU2010260208B2/en active Active
- 2010-06-15 RU RU2012101214/15A patent/RU2012101214A/ru unknown
- 2010-06-15 CN CN2010800362888A patent/CN102802608A/zh active Pending
- 2010-06-15 EP EP10727611.5A patent/EP2442791B1/en active Active
- 2010-06-15 WO PCT/US2010/038660 patent/WO2010147978A1/en not_active Ceased
- 2010-06-15 EP EP19158695.7A patent/EP3520776A1/en active Pending
- 2010-06-15 LT LTEP10727611.5T patent/LT2442791T/lt unknown
- 2010-06-15 HU HUE10727611A patent/HUE048542T2/hu unknown
- 2010-06-15 JP JP2012516197A patent/JP5775071B2/ja active Active
- 2010-06-15 ES ES10727611T patent/ES2769357T3/es active Active
- 2010-06-15 CA CA2765413A patent/CA2765413A1/en not_active Abandoned
-
2011
- 2011-11-17 IL IL216421A patent/IL216421A0/en unknown
- 2011-12-19 ZA ZA2011/09334A patent/ZA201109334B/en unknown
-
2013
- 2013-07-02 US US13/933,718 patent/US20140030330A1/en not_active Abandoned
-
2014
- 2014-05-19 US US14/281,041 patent/US20140335178A1/en not_active Abandoned
-
2017
- 2017-03-30 US US15/474,296 patent/US20170202826A1/en not_active Abandoned
-
2020
- 2020-02-25 CY CY20201100172T patent/CY1122685T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2010260208B2 (en) | 2014-11-13 |
| HRP20200297T1 (hr) | 2020-05-29 |
| ES2769357T3 (es) | 2020-06-25 |
| EP2442791B1 (en) | 2019-11-27 |
| EP2442791A1 (en) | 2012-04-25 |
| DK2442791T3 (da) | 2020-03-02 |
| LT2442791T (lt) | 2020-02-25 |
| PT2442791T (pt) | 2020-02-06 |
| ZA201109334B (en) | 2014-05-28 |
| RU2012101214A (ru) | 2013-07-27 |
| JP2012530141A (ja) | 2012-11-29 |
| HUE048542T2 (hu) | 2020-08-28 |
| MX2011013080A (es) | 2012-01-20 |
| US20140030330A1 (en) | 2014-01-30 |
| WO2010147978A1 (en) | 2010-12-23 |
| PL2442791T3 (pl) | 2020-05-18 |
| KR20120029428A (ko) | 2012-03-26 |
| US20140335178A1 (en) | 2014-11-13 |
| SI2442791T1 (sl) | 2020-03-31 |
| CN102802608A (zh) | 2012-11-28 |
| CA2765413A1 (en) | 2010-12-23 |
| SMT202000093T1 (it) | 2020-03-13 |
| JP5775071B2 (ja) | 2015-09-09 |
| SG176785A1 (en) | 2012-01-30 |
| EP3520776A1 (en) | 2019-08-07 |
| US20170202826A1 (en) | 2017-07-20 |
| IL216421A0 (en) | 2012-02-29 |
| ES2769357T8 (es) | 2020-08-06 |
| AU2010260208A1 (en) | 2011-12-15 |
| CY1122685T1 (el) | 2021-03-12 |
| US20120087978A1 (en) | 2012-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1010739A2 (pt) | formas de dosagens de apixaban. | |
| BRPI1009415A2 (pt) | escova de dentes. | |
| DK2462134T3 (da) | N1-sulfonyl-5-fluorpyrimidinonderivater | |
| BRPI1016032A2 (pt) | conjunto dual de tensionador. | |
| BRPI1008023A2 (pt) | forma de dosagem sólida | |
| HRP20180429T1 (hr) | Raspršivač | |
| BRPI0922804A2 (pt) | formas de dosagem sólidas de bendamustina | |
| BRPI1016190A2 (pt) | compostos farmacêuticos. | |
| EP2393836A4 (en) | SAM-6 VARIANTS, TARGET AND METHODS OF USING SAME | |
| BRPI1016245A2 (pt) | Preparação de c-pirazina-metilaminas. | |
| FR2957060B1 (fr) | Distributeur de comprimes. | |
| FR2943077B1 (fr) | Plaque de passage. | |
| IT1392987B1 (it) | Valvola di dosaggio antigocciolamento | |
| TH93312B (th) | ขวด | |
| ITLE20090014A1 (it) | Autostoppista d.o.c. | |
| ES1069922Y (es) | Anillo | |
| ES1072578Y (es) | Anillo percutor | |
| TH93146B (th) | ขวด | |
| CN301360184S (zh) | 瓶 | |
| UA18454S (uk) | Пляшка | |
| UA19168S (uk) | Пляшка | |
| UA19529S (uk) | Пляшка | |
| UA18757S (uk) | Пляшка | |
| UA18825S (uk) | Пляшка | |
| UA18908S (uk) | Пляшка |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |